Merck & Co., Inc.

Merck & Co., Inc. Overview

Company Headquarters: New Jersey, US

Founded: 1891

Workforce: ~69,000

Company Working: Merck & Co., Inc. (Merck) is a leading global biopharmaceutical company that develops prescription medicines, vaccines, biologic therapies, and animal health products. The company operates in more than 140 countries to deliver innovative health solutions. It operates through pharmaceutical, animal health, and healthcare services segment. The pharmaceutical segment includes human health pharmaceutical and vaccine products. The animal health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment, and control of diseases in livestock and companion animal species, which it sells to veterinarians, distributors, and animal producers. The healthcare services segment offers services and solutions that focus on engagement, health analytics, and clinical services to improve the value of care delivered to patients.

Strategy

Merck focuses on developing a diversified product portfolio by the innovation and development of products, thus delivering integrated solutions to large healthcare customers. It is engaged in making externally sourced programs a more significant component of its pipeline strategy, with a strong focus on internal research and external alliance through collaborations. It aims to increase its product portfolio via R&D investments. The company is focused on acquisitions and partnerships with established players. The company also emphasizes specialty products in healthcare, life science, and performance materials.

Company Snapshot

$41,518M

Revenue

69,000

Employees

1891

Founded

New Jersey, US

Headquarters

SWOT Analysis

Strengths

Strong R&D base
Customer loyalty and brand visibility
Improved performance of the pharmaceuticals segment
Strong R&D investments
Global presence
Well-known industry associations
Trusted partnerships and associations with medical service agencies
Well recognized brand
Strategic collaborations and partnerships to achieve the company’s goals
Skilled workforce

Weaknesses

High cost of products
Limited product range for the glioblastoma treatment
Over dependence on the pharmaceutical segment
Significant reliance on key products
Product recalls dulling the brand image
High R&D expenditure
Large business segment is difficult to handle
Limited product range for the allergic rhinitis market
Limited PEGylated products

Opportunities

Mergers & acquisitions
Product launches
Encourage inventive concepts and solutions
New product launches
Increase in the demand for body building drugs
Innovative product development

Threats

Intense rivalry with other key players
Issues regarding outsourcing of products
Intense competition
Industry amalgamation intensify competition
Reimbursement policies
Patent expiration
Stringent government regulatory control

Key Developments

Date	Approach	Development
–	Acquisition	Merck entered into a definitive agreement to acquire Peloton Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company focused on the development of novel small molecule therapeutic candidates targeting hypoxia-inducible factor-2α (HIF-2α) for the treatment of patients with cancer and other non-oncology diseases. With this acquisition, the company focuses on the expansion of its oncology business.
–	Product Development	Peloton Therapeutics, Inc. is identifying the maximum tolerated dose (MTD) of PT2977 Tablets in patients with glioblastoma multiforme. Currently, the study is in Phase 1. This study is being carried out to expand its product portfolio.
March 2019	Collaboration	Merck entered into a collaboration with strategic Eisai Co. for the development and commercialization of Lenvima oncology products.
June 2018	Approval	The company received FDA approval for Keytruda for the treatment of refractory primary mediastinal large B-cell lymphoma.
–	Agreement	Merck & Co., Inc. and Perrigo entered into an agreement over product rights of Nasonex for the US. This enabled the company to expand its product portfolio.
March 2019	Acquisition	Merck acquired Immune Design. Immune Design deals with immunotherapy products. Hence, these products have also been added to the immunotherapy related products range of Merck.
June 2018	Acquisition	Merck acquired Viralytics Limited, an Australian company. The core business of Viralytics Limited is related to oncolytic immunotherapy treatments for a range of cancers. This business acquisition has contributed to strengthening Merck’s product range and related markets.

Product Offering

Merck & Co., Inc.
- Chemotherapy
- PEGylated Drugs
- Allergic Rhinitis
- Pain Management

Financial Performance

What our clients say

Trusted by forward-thinking businesses
for data-driven intelligence

Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.

Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.

Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.

Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.

Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.

Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.

Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.

Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!

Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.

Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.